{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T20:05:07Z","timestamp":1789070707616,"version":"build-2803163510"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,4,6]],"date-time":"2024-04-06T00:00:00Z","timestamp":1712361600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,4,6]],"date-time":"2024-04-06T00:00:00Z","timestamp":1712361600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflammopharmacol"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s10787-024-01453-8","type":"journal-article","created":{"date-parts":[[2024,4,6]],"date-time":"2024-04-06T07:02:05Z","timestamp":1712386925000},"page":"1777-1789","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Atopic dermatitis: treatment and innovations in immunotherapy"],"prefix":"10.1007","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9298-6783","authenticated-orcid":false,"given":"Francesco","family":"Ferrara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6528-2171","authenticated-orcid":false,"given":"Andrea","family":"Zovi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9488-6057","authenticated-orcid":false,"given":"Maurizio","family":"Capuozzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Langella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,6]]},"reference":[{"key":"1453_CR1","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1124\/dmd.122.000829","volume":"50","author":"JN Bauman","year":"2022","unstructured":"Bauman JN, Doran AC, King-Ahmad A, Sharma R, Walker GS, Lin J et al (2022) The pharmacokinetics, metabolism, and clearance mechanisms of abrocitinib, a selective Janus kinase inhibitor, in humans. Drug Metab Dispos 50:1106\u20131118","journal-title":"Drug Metab Dispos"},{"key":"1453_CR2","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s40257-020-00527-x","volume":"21","author":"LA Beck","year":"2020","unstructured":"Beck LA, Tha\u00e7i D, Deleuran M, Blauvelt A, Bissonnette R, de Bruin-Weller M et al (2020) Dupilumab provides favorable safety and sustained efficacy for up to 3 years in an open-label study of adults with moderate-to-severe atopic dermatitis. Am J Clin Dermatol 21:567\u2013577","journal-title":"Am J Clin Dermatol"},{"key":"1453_CR3","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/j.jaci.2019.06.047","volume":"144","author":"R Bissonnette","year":"2019","unstructured":"Bissonnette R, Pavel AB, Diaz A, Werth JL, Zang C, Vranic I et al (2019) Crisaborole and atopic dermatitis skin biomarkers: an intrapatient randomized trial. J Allergy Clin Immunol 144:1274\u20131289","journal-title":"J Allergy Clin Immunol"},{"key":"1453_CR4","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","volume":"389","author":"A Blauvelt","year":"2017","unstructured":"Blauvelt A, de Bruin-Weller M, Gooderham M, Cather JC, Weisman J, Pariser D et al (2017) Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet 389:2287\u20132303","journal-title":"Lancet"},{"key":"1453_CR5","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/j.jaad.2022.07.019","volume":"87","author":"A Blauvelt","year":"2022","unstructured":"Blauvelt A, Langley RG, Lacour JP, Toth D, Laquer V, Beissert S et al (2022) Long-term 2 year safety and efficacy of tralokinumab in adults with moderate-to-severe atopic dermatitis: interim analysis of the ECZTEND open-label extension trial. J Am Acad Dermatol 87:815\u2013824","journal-title":"J Am Acad Dermatol"},{"issue":"14","key":"1453_CR6","doi-asserted-by":"publisher","first-page":"1201669","DOI":"10.3389\/fimmu.2023.1201669","volume":"18","author":"EH Chang","year":"2023","unstructured":"Chang EH, Carnevale D, Chavan SS (2023) Editorial: understanding and targeting neuro-immune interactions within disease and inflammation. Front Immunol 18(14):1201669. https:\/\/doi.org\/10.3389\/fimmu.2023.1201669","journal-title":"Front Immunol"},{"issue":"11","key":"1453_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e22014","volume":"9","author":"Q Chen","year":"2023","unstructured":"Chen Q, Cui L, Hu Y, Chen Z, Gao Y, Shi Y (2023) Short-term efficacy and safety of biologics and Janus kinase inhibitors for patients with atopic dermatitis: a systematic review and meta-analysis. Heliyon 9(11):e22014. https:\/\/doi.org\/10.1016\/j.heliyon.2023.e22014","journal-title":"Heliyon"},{"issue":"9","key":"1453_CR8","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.3390\/microorganisms11092160","volume":"11","author":"A Colletti","year":"2023","unstructured":"Colletti A, Pellizzato M, Cicero AF (2023) The possible role of probiotic supplementation in inflammation: a narrative review. Microorganisms 11(9):2160. https:\/\/doi.org\/10.3390\/microorganisms11092160","journal-title":"Microorganisms"},{"key":"1453_CR9","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1111\/bjd.19460","volume":"184","author":"MJ Cork","year":"2021","unstructured":"Cork MJ, Tha\u00e7i D, Eichenfield LF, Arkwright PD, Sun X, Chen Z, Akinlade B et al (2021) Dupilumab provides favourable long-term safety and efficacy in children aged \u22656 to <12 years with uncontrolled severe atopic dermatitis: results from an open-label phase IIa study and subsequent phase III open-label extension study. Br J Dermatol 184:857\u2013870","journal-title":"Br J Dermatol"},{"key":"1453_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaci.2018.10.032","volume":"143","author":"T Czarnowicki","year":"2019","unstructured":"Czarnowicki T, He H, Krueger JG, Guttman-Yassky E (2019) Atopic dermatitis endotypes and implications for targeted therapeutics. J Allergy Clin Immunol 143:1\u201311","journal-title":"J Allergy Clin Immunol"},{"key":"1453_CR11","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1111\/bjd.16156","volume":"178","author":"M de Bruin-Weller","year":"2018","unstructured":"de Bruin-Weller M, Tha\u00e7i D, Smith CH, Reich K, Cork MJ, Radin A, Zhang Q et al (2018) Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAF\u00c9). Br J Dermatol 178:1083\u20131101","journal-title":"Br J Dermatol"},{"issue":"1","key":"1453_CR12","doi-asserted-by":"publisher","first-page":"111","DOI":"10.3390\/pharmaceutics16010111","volume":"16","author":"A Drakos","year":"2024","unstructured":"Drakos A, Torres T, Vender R (2024) Emerging oral therapies for the treatment of psoriasis: a review of pipeline agents. Pharmaceutics 16(1):111. https:\/\/doi.org\/10.3390\/pharmaceutics16010111","journal-title":"Pharmaceutics"},{"key":"1453_CR13","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1038\/s41467-021-21383-1","volume":"12","author":"R Duhen","year":"2021","unstructured":"Duhen R, Ballesteros-Merino C, Frye AK, Tran E, Shu-Ching Chang T, Koguchi Y et al (2021) Neoadjuvant anti-OX40 (MEDI6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cells. Nat Commun 12:1047","journal-title":"Nat Commun"},{"issue":"6","key":"1453_CR14","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1007\/s12012-021-09649-y","volume":"21","author":"F Ferrara","year":"2021","unstructured":"Ferrara F, Vitiello A (2021) Scientific Hypothesis for treatment of COVID-19\u2019s lung lesions by adjusting ACE\/ACE2 Imbalance. Cardiovasc Toxicol 21(6):498\u2013503. https:\/\/doi.org\/10.1007\/s12012-021-09649-y","journal-title":"Cardiovasc Toxicol"},{"key":"1453_CR15","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1111\/imm.13120","volume":"158","author":"K Furue","year":"2019","unstructured":"Furue K, Ito T, Tsuji G, Ulzii D, Vu YH, Kido-Nakahara M et al (2019) The IL-13-OVOL1-FLG axis in atopic dermatitis. Immunology 158:281\u2013286","journal-title":"Immunology"},{"key":"1453_CR16","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1001\/jamadermatol.2019.2855","volume":"155","author":"MJ Gooderham","year":"2019","unstructured":"Gooderham MJ, Forman SB, Bissonnette R, Beebe JS, Zhang W, Banfeld C et al (2019) Efficacy and safety of oral janus kinase 1 inhibitor abrocitinib for patients with atopic dermatitis: a phase 2 randomized clinical trial. JAMA Dermatol 155:1371\u20131379","journal-title":"JAMA Dermatol"},{"key":"1453_CR17","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1111\/bjd.20832","volume":"186","author":"J Gutermuth","year":"2022","unstructured":"Gutermuth J, Pink AE, Worm M, Soldbro L, Bjerreg\u00e5rd \u00d8land C, Weidinger S et al (2022) Tralokinumab plus topical corticosteroids in adults with severe atopic dermatitis and inadequate response to or intolerance of ciclosporin A: a placebo-controlled, randomized, phase III clinical trial (ECZTRA 7). Br J Dermatol 186:440\u2013452","journal-title":"Br J Dermatol"},{"key":"1453_CR18","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.jaci.2018.11.053","volume":"144","author":"E Guttman-Yassky","year":"2019","unstructured":"Guttman-Yassky E, Pavel AB, Zhou L, Estrada YD, Zhang N, Xu H et al (2019a) GBR 830, an anti-OX40, improves skin gene signatures and clinical scores in patients with atopic dermatitis. J Allergy Clin Immunol 144:482-93e7","journal-title":"J Allergy Clin Immunol"},{"key":"1453_CR19","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.jaad.2018.01.018","volume":"80","author":"E Guttman-Yassky","year":"2019","unstructured":"Guttman-Yassky E, Silverberg JI, Nemoto O, Forman SB, Wilke A, Prescilla R et al (2019b) Baricitinib in adult patients with moderate-to-severe atopic dermatitis: a phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study. J Am Acad Dermatol 80:913-21e9","journal-title":"J Am Acad Dermatol"},{"key":"1453_CR20","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1001\/jamadermatol.2020.0079","volume":"156","author":"E Guttman-Yassky","year":"2020","unstructured":"Guttman-Yassky E, Blauvelt A, Eichenfeld LF, Paller AS, Armstrong AW, Drew J et al (2020a) Efficacy and safety of lebrikizumab, a high-affinity interleukin 13 inhibitor, in adults with moderate to severe atopic dermatitis: a phase 2b Randomized Clinical Trial. JAMA Dermatol 156:411\u2013420","journal-title":"JAMA Dermatol"},{"issue":"145","key":"1453_CR21","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.jaci.2019.11.025","volume":"2020","author":"E Guttman-Yassky","year":"2020","unstructured":"Guttman-Yassky E, Tha\u00e7i D, Pangan AL, Hong HC, Paap KA, Reich A et al (2020b) Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial. J Allergy Clin Immunol 2020(145):877\u2013884","journal-title":"J Allergy Clin Immunol"},{"key":"1453_CR22","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/cea.13491","volume":"50","author":"H Harb","year":"2019","unstructured":"Harb H, Chatila TA (2019) Mechanisms of dupilumab. Clin Exp Allergy 50:5\u201314","journal-title":"Clin Exp Allergy"},{"issue":"13","key":"1453_CR23","doi-asserted-by":"publisher","first-page":"1075192","DOI":"10.3389\/fimmu.2022.1075192","volume":"8","author":"S Kwon","year":"2022","unstructured":"Kwon S (2022) Molecular dissection of Janus kinases as drug targets for inflammatory diseases. Front Immunol 8(13):1075192. https:\/\/doi.org\/10.3389\/fimmu.2022.1075192","journal-title":"Front Immunol"},{"key":"1453_CR24","doi-asserted-by":"publisher","first-page":"e150","DOI":"10.1111\/jdv.17705","volume":"36","author":"G Licata","year":"2022","unstructured":"Licata G, Gambardella A, Tancredi V, Calabrese G, De Rosa A, Alfano R et al (2022) Face atopic dermatitis resistant to dupilumab: a case series of three patients successfully treated with upadacitinib. J Eur Acad Dermatol Venereol 36:e150\u2013e152","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1453_CR25","doi-asserted-by":"publisher","DOI":"10.1136\/ejhpharm-2021-003202","author":"L Mazzoleni","year":"2022","unstructured":"Mazzoleni L, Borsino C, Zovi A (2022) Study of overall survival associated with nintedanib and pirfenidone in patients with idiopathic pulmonary fibrosis: a real-life comparison. Eur J Hosp Pharm. https:\/\/doi.org\/10.1136\/ejhpharm-2021-003202","journal-title":"Eur J Hosp Pharm"},{"key":"1453_CR26","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1177\/1060028019839650","volume":"53","author":"A Mogul","year":"2019","unstructured":"Mogul A, Corsi K, McAuliffe L (2019) Baricitinib: the second FDA-approved JAK inhibitor for the treatment of rheumatoid arthritis. Ann Pharmacother 53:947\u2013953","journal-title":"Ann Pharmacother"},{"key":"1453_CR27","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1111\/bjd.14207","volume":"174","author":"O Nemoto","year":"2016","unstructured":"Nemoto O, Furue M, Nakagawa H, Shiramoto M, Hanada R, Matsuki S et al (2016) The first trial of CIM331, a humanized antihuman interleukin-31 receptor A antibody, in healthy volunteers and patients with atopic dermatitis to evaluate safety, tolerability and pharmacokinetics of a single dose in a randomized, double-blind, placebo- controlled study. Br J Dermatol 174:296\u2013304","journal-title":"Br J Dermatol"},{"key":"1453_CR28","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1007\/s40265-020-01335-7","volume":"80","author":"M Newsom","year":"2020","unstructured":"Newsom M, Bashyam AM, Balogh EA, Feldman SR, Strowd LC (2020) New and emerging systemic treatments for atopic dermatitis. Drugs 80:1041\u20131052","journal-title":"Drugs"},{"key":"1453_CR29","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s40272-021-00459-x","volume":"23","author":"AS Paller","year":"2021","unstructured":"Paller AS, Wollenberg A, Siegfried E, Tha\u00e7i D, Cork MJ, Arkwright PD et al (2021) Laboratory Safety of dupilumab in patients aged 6\u201311 years with severe atopic dermatitis: results from a phase iii clinical trial. Paediatr Drugs 23:515\u2013527","journal-title":"Paediatr Drugs"},{"key":"1453_CR30","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s41927-018-0031-x","volume":"2","author":"JM Parmentier","year":"2018","unstructured":"Parmentier JM, Voss J, Graff C, Schwartz A, Argiriadi M, Freidman M et al (2018) In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494). BMC Rheumatol 2:23","journal-title":"BMC Rheumatol"},{"key":"1453_CR31","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s40257-021-00597-5","volume":"22","author":"C Patruno","year":"2021","unstructured":"Patruno C, Fabbrocini G, Longo G, Argenziano G, Ferrucci SM, Stingeni L et al (2021a) Effectiveness and safety of long-term dupilumab treatment in elderly patients with atopic dermatitis: a multicenter real-life observational study. Am J Clin Dermatol 22:581\u2013586","journal-title":"Am J Clin Dermatol"},{"key":"1453_CR32","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1111\/jdv.17094","volume":"35","author":"C Patruno","year":"2021","unstructured":"Patruno C, Napolitano M, Argenziano G, Peris K, Ortoncelli M, Girolomoni G et al (2021b) DADE-Dupilumab for Atopic Dermatitis of the Elderly study group. Dupilumab therapy of atopic dermatitis of the elderly: a multicentre, real-life study. J Eur Acad Dermatol Venereol 35:958\u2013964","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1453_CR33","unstructured":"Pfizer announces positive top-line results from phase 3 study of investigational oral Jak1 candidate, abrocitinib (Pf-04965842), in patients aged 12 and older with moderate to severe atopic dermatitis (2019) Disponibile on line su: ultimo access [10 november 2022]. https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer_announces_positive_top_line_results_from_phase_3_study_of_investigational_oral_jak1_candidate_abrocitinib_pf_04965842_in_patients_aged_12_and_older_with_moderate_to_severe_atopic_dermatitis"},{"key":"1453_CR34","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1016\/S0140-6736(21)00589-4","volume":"397","author":"K Reich","year":"2021","unstructured":"Reich K, Teixeira HD, de Bruin-Weller M, Bieber T, Soong W, Kabashima K et al (2021) Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 397:2169\u20132181","journal-title":"Lancet"},{"key":"1453_CR35","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1056\/NEJMoa1606490","volume":"376","author":"T Ruzicka","year":"2017","unstructured":"Ruzicka T, Hanifn JM, Furue M, Pulka G, Mlynarczyk I, Wollenberg A, XCIMAStudyGroup et al (2017) Anti-interleukin-31 receptor A antibody for atopic dermatitis. N Engl J Med 376:826\u2013835","journal-title":"N Engl J Med"},{"key":"1453_CR36","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1080\/17512433.2018.1449642","volume":"11","author":"M Seegr\u00e4ber","year":"2018","unstructured":"Seegr\u00e4ber M, Srour J, Walter A, Knop M, Wollenberg A (2018) Dupilumab for treatment of atopic dermatitis. Expert Rev Clin Pharmacol 11:467\u2013474","journal-title":"Expert Rev Clin Pharmacol"},{"key":"1453_CR37","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.det.2017.02.005","volume":"35","author":"JI Silverberg","year":"2017","unstructured":"Silverberg JI, Kantor R (2017) The role of interleukins 4 and\/or 13 in the pathophysiology and treatment of atopic dermatitis. Dermatol Clin 35:327\u2013334","journal-title":"Dermatol Clin"},{"key":"1453_CR38","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.jaci.2019.08.013","volume":"145","author":"JI Silverberg","year":"2019","unstructured":"Silverberg JI, Pinter A, Pulka G, Poulin Y, Bouaziz JD, Wollenberg A et al (2019) Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus. J Allergy Clin Immunol 145:173\u2013182","journal-title":"J Allergy Clin Immunol"},{"key":"1453_CR39","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1111\/bjd.19573","volume":"184","author":"JI Silverberg","year":"2021","unstructured":"Silverberg JI, Toth D, Bieber T, Alexis AF, Elewski BE, Pink AE, ECZTRA3studyinvestigators et al (2021) Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial. Br J Dermatol 184:450\u2013463","journal-title":"Br J Dermatol"},{"key":"1453_CR40","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1016\/j.jaip.2021.11.034","volume":"10","author":"JI Silverberg","year":"2022","unstructured":"Silverberg JI, Rubini NPM, Pires MC, Rossi AB, Zhang A, Chen Z et al (2022) Dupilumab treatment reduces hospitalizations in adults with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol Pract 10:1279\u201385.e1","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1453_CR41","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","volume":"375","author":"EL Simpson","year":"2016","unstructured":"Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, SOLO1andSOLO2Investigators et al (2016) Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med 375:2335\u20132348","journal-title":"N Engl J Med"},{"key":"1453_CR42","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.jaad.2018.01.017","volume":"78","author":"EL Simpson","year":"2018","unstructured":"Simpson EL, Flohr C, Eichenfield LF, Bieber T, Sofen H, Taieb A et al (2018) Efficacy and safety of lebrikizumab (an antiIL-13 monoclonal antibody) in adults with moderate- to-severe atopic dermatitis inadequately controlled by topical corticosteroids: a randomized, placebo-controlled phase II trial (TREBLE). J Am Acad Dermatol 78:863-71e11","journal-title":"J Am Acad Dermatol"},{"key":"1453_CR43","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1001\/jamadermatol.2019.3336","volume":"156","author":"EL Simpson","year":"2020","unstructured":"Simpson EL, Paller AS, Siegfried EC, Boguniewicz M, Sher L, Gooderham MJ et al (2020) Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial. JAMA Dermatol 156:44\u201356","journal-title":"JAMA Dermatol"},{"key":"1453_CR44","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1001\/jamadermatol.2022.0029","volume":"158","author":"EL Simpson","year":"2022","unstructured":"Simpson EL, Papp KA, Blauvelt A, Chu CY, Hong HC, Katoh N et al (2022) Efficacy and safety of upadacitinib in patients with moderate to severe atopic dermatitis: analysis of follow-up data from the measure up 1 and measure up 2 randomized clinical trials. JAMA Dermatol 158:404\u2013413","journal-title":"JAMA Dermatol"},{"issue":"4","key":"1453_CR45","doi-asserted-by":"publisher","first-page":"3494","DOI":"10.3390\/ijms24043494","volume":"24","author":"A Stec","year":"2023","unstructured":"Stec A, Sikora M, Maciejewska M, Paralusz-Stec K, Michalska M, Sikorska E et al (2023) Bacterial metabolites: a link between gut microbiota and dermatological diseases. Int J Mol Sci 24(4):3494. https:\/\/doi.org\/10.3390\/ijms24043494","journal-title":"Int J Mol Sci"},{"key":"1453_CR46","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1016\/j.jaci.2015.03.003","volume":"135","author":"M Suarez-Farinas","year":"2015","unstructured":"Suarez-Farinas M, Ungar B, da Rosa CJ, Ewald DA, Rozenblit M, Gonzalez J et al (2015) RNA sequencing atopic dermatitis transcriptome profling provides insights into novel disease mechanisms with potential therapeutic implications. J Allergy Clin Immunol 135:1218\u20131227","journal-title":"J Allergy Clin Immunol"},{"key":"1453_CR47","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1111\/bjd.18163","volume":"181","author":"H Uchida","year":"2019","unstructured":"Uchida H, Kamata M, Mizukawa I, Watanabe A, Agematsu A, Nagata M et al (2019) Real- world efectiveness and safety of dupilumab for the treatment of atopic dermatitis in Japanese patients: a single-centre retrospective study. Br J Dermatol 181:1083\u20131085","journal-title":"Br J Dermatol"},{"issue":"1","key":"1453_CR48","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s00210-021-02169-0","volume":"395","author":"A Vitiello","year":"2022","unstructured":"Vitiello A, Ferrara F (2022) Association and pharmacological synergism of the triple drug therapy baricitinib\/remdesivir\/rhACE2 for the management of COVID-19 infection. Naunyn Schmiedebergs Arch Pharmacol 395(1):99\u2013104. https:\/\/doi.org\/10.1007\/s00210-021-02169-0","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"20","key":"1453_CR49","doi-asserted-by":"publisher","first-page":"5167","DOI":"10.3390\/cancers14205167","volume":"14","author":"A Vitiello","year":"2022","unstructured":"Vitiello A, Ferrara F, Lasala R, Zovi A (2022) Precision medicine in the treatment of locally advanced or metastatic urothelial cancer: new molecular targets and pharmacological therapies. Cancers (Basel) 14(20):5167. https:\/\/doi.org\/10.3390\/cancers14205167","journal-title":"Cancers (Basel)"},{"key":"1453_CR50","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1111\/ijd.14573","volume":"59","author":"C Wang","year":"2020","unstructured":"Wang C, Kraus CN, Patel KG, Ganesan AK, Grando SA (2020) Realworld experience of dupilumab treatment for atopic dermatitis in adults: a retrospective analysis of patients records. Int J Dermatol 59:253\u2013256","journal-title":"Int J Dermatol"},{"key":"1453_CR51","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.jaci.2018.05.029","volume":"143","author":"A Wollenberg","year":"2019","unstructured":"Wollenberg A, Howell MD, Guttman-Yassky E, Silverberg JI, Kell C, Ranade K et al (2019) Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb. J Allergy Clin Immunol 143:135\u2013141","journal-title":"J Allergy Clin Immunol"},{"key":"1453_CR52","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/bjd.19574","volume":"184","author":"A Wollenberg","year":"2021","unstructured":"Wollenberg A, Blauvelt A, Guttman-Yassky E, Worm M, Lynde C, ECZTRA 1 and ECZTRA 2 study investigators et al (2021) Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol 184:437\u2013449","journal-title":"Br J Dermatol"},{"key":"1453_CR53","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1001\/jamadermatol.2019.3617","volume":"156","author":"M Worm","year":"2020","unstructured":"Worm M, Simpson EL, Tha\u00e7i D, Bissonnette R, Lacour JP, Beissert S et al (2020) Efficacy and safety of multiple dupilumab dose regimens after initial successful treatment in patients with atopic dermatitis: a randomized clinical trial. JAMA Dermatol 156:131\u2013143","journal-title":"JAMA Dermatol"},{"issue":"1","key":"1453_CR54","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/s41392-023-01468-7","volume":"8","author":"C Xue","year":"2023","unstructured":"Xue C, Yao Q, Gu X, Shi Q, Yuan X, Chu Q et al (2023) Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer. Signal Transduct Target Ther 8(1):204. https:\/\/doi.org\/10.1038\/s41392-023-01468-7","journal-title":"Signal Transduct Target Ther"}],"container-title":["Inflammopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-024-01453-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10787-024-01453-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-024-01453-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T15:08:08Z","timestamp":1716995288000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10787-024-01453-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,6]]},"references-count":54,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["1453"],"URL":"https:\/\/doi.org\/10.1007\/s10787-024-01453-8","relation":{},"ISSN":["0925-4692","1568-5608"],"issn-type":[{"value":"0925-4692","type":"print"},{"value":"1568-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,6]]},"assertion":[{"value":"22 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for participate"}},{"value":"The authors consent to the publication of the manuscript.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publish"}},{"value":"The authors declare that the opinions expressed are of a personal nature and do not in any way commit the responsibility of the Administrations to which they belong.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Other"}}]}}